FutuRx Portfolio

  • A2i Therapeutics

    A2i Therapeutics Ltd. is a joint venture of FutuRx and Atomwise, designed to utilize Atomwise’s AI platform, AtomNet® technology, to target ADAR1, a key protein involved in controlling the innate immune response, neurological disorders, metabolic diseases and potentially a key target for immuno-oncology and neurological homeostasis. Scientific Approach A2i Therapeutics is developing small molecule inhibitors […]

  • Bsense Bio Therapeutics

    Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety.

  • CatchMe Therapeutics

    CSO: Dr. Yael Tsalenchuck CatchMe Therapeutics develops a novel class of precision medicines that targets the epitranscriptome machinery. The emerging field of RNA epitranscriptomics refers to a set of RNA modifying proteins and modified-RNA binding proteins that control different aspects of RNA biology and holds great potential for new cancer therapeutics. Scientific Background During the […]

  • Circuit-Bio

    Circuit-Bio is a synthetic biology company developing an innovative unique platform of logical gene circuits for cancer immunotherapy. The Company’s platform focuses on generating gene circuits able to locally and accurately produce a combination of multiple immune-stimulating proteins (immunomodulators) exclusively expressed in targeted tumor cells. Thus, the circuit selectively converts cancer cells into ‘Trojan horses’ utilize […]

  • Epeius Pharma

    Epeius pharma is a cell and gene therapy company developing next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS). Efficient and predictable therapeutics delivery is particularly challenging in neurological diseases due to the blood-brain barrier (BBB), which tightly regulates the transport of molecules to the brain, and blocks the […]

  • Ramino-Bio

    OVERVIEW Ramino Bio is an Israeli private biotech company developing an oral drug to treat metabolic diseases. Per a well-thought-out strategy, its first indication is Maple Syrup Urine Disease (MSUD), a rare genetic disease that leads to severe neurological failure. Furthermore, its unique mechanism of action heralds great promise to other metabolic disorders associated with […]

  • ReadeRx Therapeutics

    Scientific Approach ReadeRx is developing small molecule inhibitors targeting the RNA binding protein IGF2BP1 as a novel treatment for cancer. IGF2BP1 is an oncofetal RNA binding protein expressed in many types of cancers. it regulates RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. IGFB2P1 is widely expressed in development […]

  • Rnable

    RNAble is developing novel compounds that alter RNA stability through modulation of RNA epitranscriptomics for the treatment of specific cancers and rare genetic diseases with nonsense mutations. SCIENTIFIC BACKGROUND RNA transcripts undergo modifications that are recognized by specific RNA binding proteins dictating their stability. Prof. Rotem Karni, RNAble inventor, discovered that targeting components of the […]

  • Selene Therapeutics

    Selene Therapeutics is pioneering a new therapeutic strategy for treating refractory epilepsy – regulation of the neuronal activity set point by reduction of the  neuronal mean firing rate (MFR). Selene aims to develop small molecule for inhibitors of Dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme located on the inner mitochondrial membrane and participating in several key […]

  • Skip Therapeutics

    Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases by applying a novel, proprietary, computational engine to directly identify patient cohorts and determine therapeutic designs. Skip’s website: www.skiptx.com SCIENTIFIC BACKGROUND Thousands of rare genetic disorders affect millions of people worldwide, however the small number of patients for each disease, further segregated by patient-specific mutations, […]

  • Symbol Therapeutics

    Symbol Therapeutics is a drug discovery company developing a novel immunoregulatory therapeutic protein, which is a modified form of the endogenous Semaphorin3A, for the treatment of Systemic Lupus Erythematosus (SLE) and other autoimmune diseases. Our proprietary modified protein is able to activate anti-inflammatory regulatory mechanisms and thereby restore normal immune homeostasis. Scientific background Autoimmune diseases […]

Incubator Graduates

  • BiomX

    Discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and topical diseases that stem from dysbiosis.

  • ImmPACT-Bio

    ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy.

  • Pi Therapeutics

    Pi Therapeutics is a preclinical-stage pharmaceutical company a first-in-class small molecule cancer drug

  • Protekt Therapeutics

    Protekt Therapeutics is a biopharmaceutical company aiming to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI)